Edgar Filing: NEOPROBE CORP - Form 8-K

NEOPROBE CORP Form 8-K October 12, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event	reported)	October 11, 2004
NEOPROBE	CORPORATION	
(Exact name of registrant as specifyed in its charter)		
Delaware	0-26520	31-1080091
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer IdentifycationNo.)
425 Metro Place North, Suite 300, Columbus, Ohio 43017		
(Address of principal executive offices) (Zip Code)		
Registrant's telephone number, includi	ng area code	(614) 793-7500
(Former name or former address, if changed since last report.)		
Check the appropriate box below if the Form 8-K fyling is intended to simultaneously satisfy the fyling obligation of the registrant under any of the following provisions (see General Instruction A.2. below):		
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
[] Soliciting material pursuant to Rul 240.14a-12)	e 14a-12 under	the Exchange Act (17 CFR
[] Pre-commencement communications pur Act (17 CFR 240.14d-2(b))	suant to Rule 1	14d-2(b) under the Exchange
[] Pre-commencement communications pur Act (17 CFR 240.13e-4(c))	ssuant to Rule 1	3e-4(c) under the Exchange

Edgar Filing: NEOPROBE CORP - Form 8-K

On October 11, 2004, the Company issued a press release entitled "Neoprobe Provides Regulatory Update on RIGS and Lymphoseek" updating the regulatory status of the Company's two oncology product clinical development programs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit

Number Exhibit Description

99.1 Press release issued October 11, 2004, entitled "Neoprobe Provides Regulatory Update on RIGS and Lymphoseek."

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neoprobe Corporation

Date: October 11, 2004 By: /s/Brent L. Larson

Brent L. Larson, Vice President Finance and

Chief Financial Officer

3